PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$1.98
-0.15 (-7.04%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 16, 2026
Smart Money Accumulation
PROK is down 8.8% this week, but smart money is accumulating calls. Top strike: $3 2026-04-17 with 670 OI. Call ratio: 85% View Scanner →
Strength: 7.8/10
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PROK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PROK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $1.98, which is considered oversold relative to its 30-day fair value range of $2.12 to $2.39.
Technical Outlook: Technically, PROK is in a strong downtrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: PROK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.50 (+228.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PROK is in a strong downtrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: PROK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.50 (+228.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.12 -
$2.39
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.0%)
- BULLISH: Trading 228.3% below Wall St target ($6.50)
- CAUTION: 5-day price weakness (-8.8%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$2.12 -
$2.39
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$2.32
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-3.11
Wall Street Target
$6.50
(+228.3%)
Last updated: February 01, 2026 4:00 PM ET
Data refreshes hourly during market hours. Next update: 5:00 PM
Data refreshes hourly during market hours. Next update: 5:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
